Literature DB >> 10678636

Fractional analysis of bronchoalveolar lavage fluid cytology in cystic fibrosis patients with normal lung function. Bronchoalveolar lavage for the evaluation of anti-inflammatory treatment (BEAT) study group.

F Ratjen1, E Rietschel, M Griese, M Ballmann, I Kleinau, G Döring, D Reinhardt, K Paul.   

Abstract

Cystic fibrosis (CF) is associated with a neutrophil dominated airway inflammation. So far bronchoalveolar lavage (BAL) studies in CF have used pooled BAL samples which may be more representative of the alveolar compartment rather than the airways. To assess whether the first sample of a BAL is more sensitive in the evaluation of airway inflammation, the authors have studied 105 stable CF patients aged 5-37 yrs with a mean forced expiratory volume in one second (FEV1) of 96+/-15% (mean+/-SD). BAL cytology of the first and pooled samples were compared to reference values obtained in children without respiratory disease. Absolute cell counts and the percentage of neutrophils were significantly increased in CF patients. If the 95% confidence interval was used as a cut-off point, 17/105 CF patients had a normal percentage of neutrophils in pooled BAL samples, but only three also had a normal percentage of neutrophils in the first BAL aliquot. Therefore, neutrophil dominated airway inflammation is more pronounced in the first, mainly bronchial, bronchoalveolar lavage sample suggesting that sequential analysis of bronchoalveolar lavage fluid may have a higher sensitivity to detect early inflammatory changes in CF patients.

Entities:  

Mesh:

Year:  2000        PMID: 10678636     DOI: 10.1183/09031936.00.15114100

Source DB:  PubMed          Journal:  Eur Respir J        ISSN: 0903-1936            Impact factor:   16.671


  12 in total

1.  Matrix metalloproteases in BAL fluid of patients with cystic fibrosis and their modulation by treatment with dornase alpha.

Authors:  F Ratjen; C-M Hartog; K Paul; J Wermelt; J Braun
Journal:  Thorax       Date:  2002-11       Impact factor: 9.139

2.  [Cystic fibrosis and associated complications].

Authors:  C Schwarz; D Staab
Journal:  Internist (Berl)       Date:  2015-03       Impact factor: 0.743

3.  BPI-ANCA in transporter associated with antigen presentation (TAP) deficiency: possible role in susceptibility to Gram-negative bacterial infections.

Authors:  H Schultz; S Schinke; J Weiss; V Cerundolo; W L Gross; S Gadola
Journal:  Clin Exp Immunol       Date:  2003-08       Impact factor: 4.330

4.  Assessment of surfactant protein A (SP-A) dependent agglutination.

Authors:  Stefanie M Heinrich; Matthias Griese
Journal:  BMC Pulm Med       Date:  2010-11-22       Impact factor: 3.317

5.  Expression, regulation and clinical significance of soluble and membrane CD14 receptors in pediatric inflammatory lung diseases.

Authors:  Veronica Marcos; Phillip Latzin; Andreas Hector; Sebastian Sonanini; Florian Hoffmann; Martin Lacher; Barbara Koller; Philip Bufler; Thomas Nicolai; Dominik Hartl; Matthias Griese
Journal:  Respir Res       Date:  2010-03-19

6.  Outcome measures for clinical trials assessing treatment of cystic fibrosis lung disease.

Authors:  Donald R VanDevanter; Michael W Konstan
Journal:  Clin Investig (Lond)       Date:  2012

7.  Sequential analysis of surfactant, lung function and inflammation in cystic fibrosis patients.

Authors:  Matthias Griese; Robert Essl; Reinhold Schmidt; Manfred Ballmann; Karl Paul; Ernst Rietschel; Felix Ratjen
Journal:  Respir Res       Date:  2005-11-07

8.  Safety of research bronchoscopy with BAL in stable adult patients with cystic fibrosis.

Authors:  Daniel Aridgides; John Dessaint; Graham Atkins; James Carroll; Alix Ashare
Journal:  PLoS One       Date:  2021-01-22       Impact factor: 3.240

Review 9.  Optimizations of In Vitro Mucus and Cell Culture Models to Better Predict In Vivo Gene Transfer in Pathological Lung Respiratory Airways: Cystic Fibrosis as an Example.

Authors:  Rosy Ghanem; Véronique Laurent; Philippe Roquefort; Tanguy Haute; Sophie Ramel; Tony Le Gall; Thierry Aubry; Tristan Montier
Journal:  Pharmaceutics       Date:  2020-12-31       Impact factor: 6.321

Review 10.  State of progress in treating cystic fibrosis respiratory disease.

Authors:  Patrick A Flume; Donald R Van Devanter
Journal:  BMC Med       Date:  2012-08-10       Impact factor: 8.775

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.